These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2006-001871-39 A PHASE II, MULTI CENTRE, DOUBLE-BLIND, RANDOMISED, PLACEBO CONTROLLED, DOSE-ESCALATION, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF CK-1827452 IN PATIENTS WITH STABLE HEART FAILURE. 2009-02-12 due-trials
Reported results 2012-004987-23 A Phase IIb, multi-national, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS) 2014-03-21 due-trials
Reported results 2014-005413-23 A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotrophic ... 2017-09-27 due-trials
Reported results 2016-002629-13 A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) who Completed VITALITY-ALS (CY 4031) 2018-10-26 due-trials
Reported results 2018-000586-37 A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability Of CK-2127107 In Patients with Amyotrophic Lateral Sclerosi... 2019-03-07 due-trials
Reported results 2018-001233-40 A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects with Heart Failure with Reduced Ejection Fraction and Decr... 2021-11-29 due-trials
Ongoing, reported early 2019-002785-12 A multi-center, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CK-3773274 in adults with symptomatic h... not-yet-due
Other 2020-003571-17 A FOLLOW-UP, OPEN-LABEL, RESEARCH EVALUATION OF SUSTAINED TREATMENT WITH AFICAMTEN (CK-3773274) IN HYPERTROPHIC CARDIOMYOPATHY (HCM) not-yet-due
Not reported 2020-004040-29 A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS) Studio Clinico Mu... 2023-07-18 due-trials
Listed as ongoing, but also has a completion date 2021-003536-92 A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricula... 2023-12-01 bad-data
Listed as ongoing, but also has a completion date and reported results 2021-004727-33 A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) 2023-06-07 bad-data